Completed

Androgen Receptor Mutations in Hormone Refractory Prostate Cancer

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being collected

Data Collection

Collected from today forward - Prospective
OtherDNA Samples
Who is being recruted

Urogenital Diseases+7

+ Genital Diseases

+ Genital Diseases, Male

See all eligibility criteria
How is the trial designed

Case-Only

Examining characteristics of individuals with a disease in order to identify genetic or environmental factors contributing to the condition.
Observational
Study Start: January 1997
See protocol details

Summary

Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 14, 2016
Sourced from a government-validated database.Claim as a partner

Study start date: January 1, 1997

Actual date on which the first participant was enrolled.

OBJECTIVES: the feasibility of collecting bone marrow biopsies from prostate cancer patients in a cooperative group setting the incidence of marrow invasion by prostate tumor in random bone marrow biopsy the influence of previous prostate radiation on obtaining prostate tumor the frequency and type of AR mutations and association of AR mutations with response to antiandrogen withdrawal.

NCT00002924
Principal SponsorAlliance for Clinical Trials in Oncology
Last updated: July 14, 2016
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details

184 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Case-only

These studies focus only on individuals who have a specific disease. Researchers examine patterns—often genetic or environmental—to uncover what might be linked to the condition.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria

Male

Biological sex of participants that are eligible to enroll.

Healthy volunteers not allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

Urogenital DiseasesGenital DiseasesGenital Diseases, MaleGenital Neoplasms, MaleNeoplasmsNeoplasms by SiteProstatic DiseasesUrogenital NeoplasmsMale Urogenital DiseasesProstatic Neoplasms

Criteria

Histologically proven adenocarcinoma of the prostate that is refractory to hormone therapy Patients who are eligible for anticancer therapy on Protocol CLB-9480, CLB-9583, CLB-9680, or CLB-9780 are also eligible for this study if they have not started treatment on those protocols

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Treatment Groups
Study Objectives

One single intervention group is designated in this study

This study does not include a placebo group 

Treatment Groups

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 49 locations

Veterans Affairs Medical Center - Birmingham

Birmingham, United StatesOpen Veterans Affairs Medical Center - Birmingham in Google Maps

University of California San Diego Cancer Center

La Jolla, United States

UCSF Cancer Center and Cancer Research Institute

San Francisco, United States

Veterans Affairs Medical Center - San Francisco

San Francisco, United States
Completed49 Study Centers